SCHEMBL5545876

SCHEMBL5545876

Cc1cccc(C=CCO[C]=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 1/20 0.45
FBP1 P09467 1/20 0.45
PTGS1 P23219 3/20 0.42
PTGS2 P35354 3/20 0.42
ALOX5 P09917 1/20 0.42
TP53 P04637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MAOA P21397 4/20 0.40
MAOB P27338 4/20 0.40
CACNA1B Q00975 1/20 0.39
PPARG P37231 1/20 0.39
IDO1 P14902 2/20 0.39
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545874 1.00 RELA (0.45) RELAFBP1PTGS1PTGS2ALOX5
SCHEMBL5542485 0.83
SCHEMBL5542488 0.83
SCHEMBL5543605 0.81 CHRM2 (0.56) RELAFBP1MAOB
SCHEMBL5543602 0.81 CHRM2 (0.56) RELAFBP1MAOB
SCHEMBL5536691 0.81 CYP1A2 (0.47) RELAFBP1MAOAMAOB
SCHEMBL5546280 0.81 NFE2L2 (0.53) RELAFBP1PTGS1PTGS2NPC1
SCHEMBL5536692 0.81 CYP1A2 (0.47) RELAFBP1MAOAMAOB
SCHEMBL5546282 0.81 NFE2L2 (0.53) RELAFBP1PTGS1PTGS2NPC1
SCHEMBL5543977 0.81 HSD17B3 (0.47) MAOAMAOBCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RELA 998/4885FBP1 1110/4885PTGS1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.